You are here

  • Home
  • Archive
  • Volume 89, Issue 4
  • A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial)

Article info

Article menu

Download PDFPDF

Multiple sclerosis
Research paper
A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial)
Free

Authors

  • Klarissa Hanja Stürner Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Neurology, Christian-Albrechts-University, Kiel, Germany PubMed articlesGoogle scholar articles
  • Jan-Patrick Stellmann Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Jan Dörr NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin and Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany PubMed articlesGoogle scholar articles
  • Friedemann Paul NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin and Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany PubMed articlesGoogle scholar articles
  • Tim Friede Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany PubMed articlesGoogle scholar articles
  • Sven Schammler Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Stefanie Reinhardt Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Susanne Gellissen Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Diagnostic and Interventional Neuroradiology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Gainet Weissflog Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Diagnostic and Interventional Neuroradiology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Tobias Djamsched Faizy Department of Diagnostic and Interventional Neuroradiology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Oliver Werz Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University, Jena, Germany PubMed articlesGoogle scholar articles
  • Sabine Fleischer Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Lea A I Vaas Fraunhofer IME Screening Port, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Frank Herrmann Evotec AG, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Ole Pless Fraunhofer IME Screening Port, Hamburg, Germany PubMed articlesGoogle scholar articles
  • Roland Martin Neuroimmunology and MS Research Section, Department of Neurology, University Hospital Zürich, Switzerland, Germany PubMed articlesGoogle scholar articles
  • Christoph Heesen Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Klarissa Hanja Stürner, Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Rosalind-Franklin-Straße 10, 24105 Kiel, Germany; klarissa.stuerner{at}uksh.de
View Full Text

Citation

Stürner KH, Stellmann J, Dörr J, et al
A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial)
Journal of Neurology, Neurosurgery & Psychiatry 2018;89:330-338.

Publication history

  • Received August 17, 2017
  • Revised October 24, 2017
  • Accepted November 17, 2017
  • First published December 16, 2017.
Online issue publication 
March 15, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.